Novartis’ digital drive continues with eye-disease app

“ZURICH (Reuters) – Novartis’s foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies” writes Midwest Communications Inc for Since patients with eye problems may face mobility issues, Novartis said this app could reduce the hassle of collecting reliable data. Several top research institutions have already developed applications, including Stanford University School of Medicine and Weill Cornell Medical College. []. In March, Narasimhan announced separate plans for up to 10 remote clinical trials by 2022 using U.S. partner Science 37’s mobile technology.

Share This:

Related posts